Dealing with Skin and Blood-Brain Barriers: The Unconventional Challenges of Mesoporous Silica Nanoparticles

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2018 Dec 6

PMID 30513731

Citations 14

Authors

Alessandra Nigro

Michele Pellegrino

Marianna Greco

Alessandra Comande

Diego Sisci

Luigi Pasqua

Antonella Leggio

Catia Morelli

Affiliations

Soon will be listed here.

Abstract

Advances in nanotechnology for drug delivery are fostering significant progress in medicine and diagnostics. The multidisciplinary nature of the nanotechnology field encouraged the development of innovative strategies and materials to treat a wide range of diseases in a highly specific way, which allows reducing the drug dosage and, consequently, improving the patient's compliance. Due to their good biocompatibility, easy synthesis, and high versatility, inorganic frameworks represent a valid tool to achieve this aim. In this context, Mesoporous Silica Nanoparticles (MSNs) are emerging in the biomedical field. For their ordered porosity and high functionalizable surface, achievable with an inexpensive synthesis process and being non-hazardous to biological tissues, MSNs offer ideal solutions to host, protect, and transport drugs to specific target sites. Extensive literature exists on the use of MSNs as targeted vehicles for systemic (chemo) therapy and for imaging/diagnostic purposes. However, the aim of this review is to give an overview of the last updates on the potential applications of the MSNs for Topical Drug Delivery (TDD) and as drug delivery systems into the brain, discussing their performances and advantages in dealing with these intriguing biological barriers.

Citing Articles

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J Mater Today Bio. 2025; 31:101457.

PMID: 39896289 PMC: 11786670. DOI: 10.1016/j.mtbio.2025.101457.

How Key Alterations of Mesoporous Silica Nanoparticles Affect Anti-Lung Cancer Therapy? A Comprehensive Review of the Literature.

Budiman A, Rusdin A, Subra L, Aulifa D Int J Nanomedicine. 2023; 18:5473-5493.

PMID: 37791322 PMC: 10542112. DOI: 10.2147/IJN.S426120.

Silica-Based Advanced Nanoparticles For Treating Ischemic Disease.

Kudaibergen D, Park H, Park J, Im G, Lee J, Joung Y Tissue Eng Regen Med. 2023; 20(2):177-198.

PMID: 36689072 PMC: 10070585. DOI: 10.1007/s13770-022-00510-z.

Bioadhesive 3D-Printed Skin Drug Delivery Polymeric Films: From the Drug Loading in Mesoporous Silica to the Manufacturing Process.

de Oliveira R, Funk N, Dos Santos J, de Oliveira T, de Oliveira E, Petzhold C Pharmaceutics. 2023; 15(1).

PMID: 36678649 PMC: 9861290. DOI: 10.3390/pharmaceutics15010020.

A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery.

Kolimi P, Narala S, Youssef A, Nyavanandi D, Dudhipala N Nanotheranostics. 2023; 7(1):70-89.

PMID: 36593800 PMC: 9760363. DOI: 10.7150/ntno.77395.

References

Tolbert S, McFadden P, Loy D . New Hybrid Organic/Inorganic Polysilsesquioxane-Silica Particles as Sunscreens. ACS Appl Mater Interfaces. 2016; 8(5):3160-74. DOI: 10.1021/acsami.5b10472. View

Solanki I, Parihar P, Mansuri M, Parihar M . Flavonoid-based therapies in the early management of neurodegenerative diseases. Adv Nutr. 2015; 6(1):64-72. PMC: 4288281. DOI: 10.3945/an.114.007500. View

Mebert A, Baglole C, Desimone M, Maysinger D . Nanoengineered silica: Properties, applications and toxicity. Food Chem Toxicol. 2017; 109(Pt 1):753-770. DOI: 10.1016/j.fct.2017.05.054. View

Cherniack E . A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders. Br J Nutr. 2012; 108(5):794-800. DOI: 10.1017/S0007114512000669. View

Bagde A, Mondal A, Singh M . Drug delivery strategies for chemoprevention of UVB-induced skin cancer: A review. Photodermatol Photoimmunol Photomed. 2017; 34(1):60-68. PMC: 8691077. DOI: 10.1111/phpp.12368. View

Vallet-Regi M, Colilla M, Izquierdo-Barba I, Manzano M . Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights. Molecules. 2018; 23(1). PMC: 5943960. DOI: 10.3390/molecules23010047. View

YOSHIKAWA , Sakaeda nee Kakutani T , Sugawara , Hirano , Stella . A novel chemical delivery system for brain targeting. Adv Drug Deliv Rev. 2000; 36(2-3):255-275. DOI: 10.1016/s0169-409x(98)00091-x. View

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Shukitt-Hale B . Blueberries and neuronal aging. Gerontology. 2012; 58(6):518-23. DOI: 10.1159/000341101. View

10.

Benezra M, Penate-Medina O, Zanzonico P, Schaer D, Ow H, Burns A . Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011; 121(7):2768-80. PMC: 3223837. DOI: 10.1172/JCI45600. View

11.

Sayed E, Haj-Ahmad R, Ruparelia K, Arshad M, Chang M, Ahmad Z . Porous Inorganic Drug Delivery Systems-a Review. AAPS PharmSciTech. 2017; 18(5):1507-1525. DOI: 10.1208/s12249-017-0740-2. View

12.

He Q, Liu J, Liang J, Liu X, Li W, Liu Z . Towards Improvements for Penetrating the Blood-Brain Barrier-Recent Progress from a Material and Pharmaceutical Perspective. Cells. 2018; 7(4). PMC: 5946101. DOI: 10.3390/cells7040024. View

13.

Schroeder U, Sommerfeld P, Ulrich S, Sabel B . Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci. 1998; 87(11):1305-7. DOI: 10.1021/js980084y. View

14.

Rizvi S, Saleh A . Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018; 26(1):64-70. PMC: 5783816. DOI: 10.1016/j.jsps.2017.10.012. View

15.

Mecocci P, Tinarelli C, Schulz R, Polidori M . Nutraceuticals in cognitive impairment and Alzheimer's disease. Front Pharmacol. 2014; 5:147. PMC: 4066843. DOI: 10.3389/fphar.2014.00147. View

16.

Elle R, Rahmani S, Lauret C, Morena M, Bidel L, Boulahtouf A . Functionalized Mesoporous Silica Nanoparticle with Antioxidants as a New Carrier That Generates Lower Oxidative Stress Impact on Cells. Mol Pharm. 2016; 13(8):2647-60. DOI: 10.1021/acs.molpharmaceut.6b00190. View

17.

Frohlich E . Value of phagocyte function screening for immunotoxicity of nanoparticles in vivo. Int J Nanomedicine. 2015; 10:3761-78. PMC: 4454219. DOI: 10.2147/IJN.S83068. View

18.

Knezevic N, Ilic N, D Okic V, Petrovic R, Janackovic D . Mesoporous Silica and Organosilica Nanomaterials as UV-Blocking Agents. ACS Appl Mater Interfaces. 2018; 10(24):20231-20236. DOI: 10.1021/acsami.8b04635. View

19.

Anirudhan T, Nair A . Temperature and ultrasound sensitive gatekeepers for the controlled release of chemotherapeutic drugs from mesoporous silica nanoparticles. J Mater Chem B. 2020; 6(3):428-439. DOI: 10.1039/c7tb02292a. View

20.

Yang L, Yin T, Liu Y, Sun J, Zhou Y, Liu J . Gold nanoparticle-capped mesoporous silica-based HO-responsive controlled release system for Alzheimer's disease treatment. Acta Biomater. 2016; 46:177-190. DOI: 10.1016/j.actbio.2016.09.010. View